Abstract

Hydroxycarboxylic acid receptor 2 (HCAR2) belongs to the family of class A G protein-coupled receptors with key roles in regulating lipolysis and free fatty acid formation in humans. It is deeply involved in many pathophysiological processes and serves as an attractive target for the treatment of cardiovascular, neoplastic, autoimmune, neurodegenerative, inflammatory, and metabolic diseases. Here, we report four cryo-EM structures of human HCAR2–Gi1 complexes with or without agonists, including the drugs niacin (2.69 Å) and acipimox (3.23 Å), the highly subtype-specific agonist MK-6892 (3.25 Å), and apo form (3.28 Å). Combined with molecular dynamics simulation and functional analysis, we have revealed the recognition mechanism of HCAR2 for different agonists and summarized the general pharmacophore features of HCAR2 agonists, which are based on three key residues R1113.36, S17945.52, and Y2847.43. Notably, the MK-6892–HCAR2 structure shows an extended binding pocket relative to other agonist-bound HCAR2 complexes. In addition, the key residues that determine the ligand selectivity between the HCAR2 and HCAR3 are also illuminated. Our findings provide structural insights into the ligand recognition, selectivity, activation, and G protein coupling mechanism of HCAR2, which shed light on the design of new HCAR2-targeting drugs for greater efficacy, higher selectivity, and fewer or no side effects.

Details

Title
Structural insights into ligand recognition and selectivity of the human hydroxycarboxylic acid receptor HCAR2
Author
Pan, Xin 1 ; Ye, Fang 2 ; Ning, Peiruo 2 ; Zhang, Zhiyi 2 ; Li, Xinyu 3 ; Zhang, Binghao 2 ; Wang, Qian 2 ; Chen, Geng 2 ; Gao, Wei 2 ; Qiu, Chen 2 ; Wu, Zhangsong 2 ; Li, Jiancheng 4 ; Zhu, Lizhe 3   VIAFID ORCID Logo  ; Xia, Jiang 5 ; Gong, Kaizheng 6 ; Du, Yang 2   VIAFID ORCID Logo 

 The Chinese University of Hong Kong, Kobilka Institute of Innovative Drug Discovery, Shenzhen Futian Biomedical Innovation R&D Center, School of Medicine, Shenzhen, China (GRID:grid.10784.3a) (ISNI:0000 0004 1937 0482); The Affiliated Hospital of Yangzhou University, Yangzhou University, Department of Cardiology, Central Laboratory, Yangzhou, China (GRID:grid.268415.c) 
 The Chinese University of Hong Kong, Kobilka Institute of Innovative Drug Discovery, Shenzhen Futian Biomedical Innovation R&D Center, School of Medicine, Shenzhen, China (GRID:grid.10784.3a) (ISNI:0000 0004 1937 0482) 
 The Chinese University of Hong Kong, Warshel Institute for Computational Biology, School of Medicine, Shenzhen, China (GRID:grid.10784.3a) (ISNI:0000 0004 1937 0482) 
 Shenzhen University, Instrumental Analysis Center, Shenzhen, China (GRID:grid.263488.3) (ISNI:0000 0001 0472 9649) 
 The Chinese University of Hong Kong, Department of Chemistry, Shatin, Hong Kong SAR, China (GRID:grid.10784.3a) (ISNI:0000 0004 1937 0482) 
 The Affiliated Hospital of Yangzhou University, Yangzhou University, Department of Cardiology, Central Laboratory, Yangzhou, China (GRID:grid.268415.c) 
Pages
118
Publication year
2023
Publication date
2023
Publisher
Springer Nature B.V.
e-ISSN
20565968
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2894163996
Copyright
© The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.